This study focuses on treating patients with resectable gastric cancer. The treatment combines several medications: spartalizumab (also known as PDR001) with a combination of drugs called FLOT, which includes fluorouracil, folinic acid (leucovorin), oxaliplatin, and docetaxel. These medications are given through intravenous infusion, which means they are delivered directly into the bloodstream through a vein.
The purpose of this research is to evaluate how well the tumor responds to treatment before surgery. The treatment is given both before and after surgery, which is known as perioperative treatment. During surgery, doctors will examine the tumor tissue to determine if any cancer cells remain after the initial treatment phase.
Patients will receive the combination of medications over multiple treatment cycles. The medications are given as solutions that are diluted and then infused into a vein. The treatment period may last up to 16 weeks, during which patients will be monitored for how well the treatment works and any side effects that may occur.
France 
